INTRODUCTION {#S1}
============

The Warburg effect has led to the misconception that the mitochondria of cancer cells are non-functional ([@R84]). It is now recognized that they are, in fact, critical for tumor growth and exhibit drastic reprogramming to support the unique metabolic and biosynthetic needs of a cancer cell ([@R66]; [@R86]; [@R87]). Mitochondrial reprogramming is characterized by elevated oxidative stress via reactive oxygen species (ROS). As the majority of ROS are produced at the mitochondrial inner membrane, the mitochondria of cancer cells are especially prone to their effects. Increased ROS can serve as signaling molecules important for oncogenesis and tumor formation ([@R14]; [@R76]). On the other hand, ROS can damage lipids, DNA, and proteins by oxidation--causing protein misfolding. In metastatic cells, the effects of ROS may be exacerbated due to anchorage-independent growth and the foreign microenvironments experienced during dissemination. Excessive ROS poses a severe risk to mitochondrial network integrity and, in turn, cancer cell viability. These observations emphasize the need for cancer cells to maintain mitochondrial fitness through adaptive mechanisms, including proteostasis, antioxidant machinery, mitochondrial biogenesis, and mitophagy.

Hormesis describes the biphasic response of a cell or organism to increasing amounts of a substance or condition. At high doses, these toxins or stressors are determinantal, but at low level exposure within the "hormetic zone," favorable biological responses are produced ([@R53]).

Mitochondrial ROS within the hormetic zone activates mitoprotective mechanisms, which paradoxically persist when the acute stress subsides--termed mitohormesis ([@R72]; [@R96]). Mitohormesis elicited by mitochondrial ROS extends lifespan in *C. elegans* and yeast ([@R5]; [@R45]; [@R94]; [@R20]; [@R83];[@R77]). In flies and worms, the mitochondrial unfolded protein response (UPR^mt^) was identified as a pathway essential for mitohormesis-induced longevity ([@R17]; [@R20]; [@R54]; [@R81]; [@R63]; [@R61]; [@R19]). The UPR^mt^ was originally discovered by the Hoogenraad group, who described retrograde signaling mediated by C/EBP homologous protein (CHOP) leading to the induction of mitochondrial proteases, such as HSP60 ([@R98]). Using HSP60 as a UPR^mt^ reporter in C. elegans, subsequent work has identified ATFS-1 and DVE-1/UBL5 as important transcriptional activators of the UPR^mt^ ([@R3]; [@R19]; [@R22]; [@R26]; [@R31], [@R32]; [@R49]; [@R50]; [@R54]; [@R61], [@R60]; [@R67]; [@R69]; [@R81]).

In mammalian cells, we reported a SIRT3-dependent axis of the UPR^mt^ that activates antioxidant genes, mitochondrial biogenesis, and mitophagy ([@R35], [@R36]; [@R37], [@R38]; [@R65]). A strikingly similar sirtuin UPR^mt^ axis exists in *C. elegans* ([@R57]). Recently, mitohormesis was described in mammalian cells using an inducible and reversible SOD2 knockdown mouse (iSOD2-KD) ([@R12]). In this study, knockdown of SOD2 in development caused increased ROS and mitohormesis, resulting in mitochondrial biogenesis and antioxidant programs ([@R12]).

In the context of development and aging, mitohormesis in the absence of underlying pathology is beneficial. In the context of cancer, however, the persistent activation of cytoprotective mechanisms by mitohormesis may favor tumor growth and progression. We initiated the current study to determine if mitohormesis occurs under endogenous oxidative stress in breast cancer and to assess its potential impact on disease progression.

Our data suggest the existence of two subpopulations of cancer cells characterized by mitochondrial ROS levels. We found that the ROS-positive subpopulation upregulates mitoprotective pathways, such as the UPR^mt^, which maintain ROS in the hormetic zone and result in increased mitochondrial fitness in a manner consistent with mitohormesis. Consequently, these cells are more resistant to oxidative stress and have increased metastatic capacity. Our data suggest that cancer cells exploit mitohormesis to enhance metastatic disease progression.

RESULTS {#S2}
=======

Mitohormesis in Primary Tumors Identifies a Metastatic Subset of Cancer Cells {#S3}
-----------------------------------------------------------------------------

Two cohorts of 3-month-old female *MTTV-rtTA/TetO-NeuNT* mice ([@R55]) were given doxycycline supplemented drinking water to generate primary mammary tumors at different rates ([Figure 1A](#F1){ref-type="fig"}). Using MitoSOX, flow cytometry was performed on primary tumors from all mice, and a distinct biphasic distribution of mitochondrial ROS was observed ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). Low (ROS−) and high ROS (ROS+) subpopulations were isolated by fluorescence-associated cell sorting (FACS) and expanded *ex vivo* ([Figure 1C](#F1){ref-type="fig"}). By transwell invasion assay, we found the ROS+ subpopulation significantly more invasive than its matched ROS− counterpart ([Figure 1D](#F1){ref-type="fig"}). Further, we found that this difference is maintained over continued passage, indicating a stable phenotype ([Figure 1D](#F1){ref-type="fig"}). This was not due to different proliferation rates ([Figure S1A](#SD1){ref-type="supplementary-material"}). After confirming no intrinsic differences in bioluminescence ([Figure S1B](#SD1){ref-type="supplementary-material"}), we performed tail vein injections to test metastasis differences *in vivo*. We found that ROS+ cells were significantly more metastatic than the ROS− subpopulation ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}). As ROS activates the UPR^mt^ ([@R65]) and correlates with an invasive phenotype ([@R37]), we probed both subpopulations directly after FACS ([Figure 1C](#F1){ref-type="fig"}) for markers of the UPR^mt^ ([Figure 1G](#F1){ref-type="fig"}). We found the ROS+ subpopulation upregulates UPR^mt^ markers, including the SIRT3 axis (SIRT3, FOXO3a, LC3, NRF1, SOD2) and the CHOP/ATF5 axis (HSP60) ([Figure 1D](#F1){ref-type="fig"}). Using an unbiased multi-omic approach, SOD1 was identified as a part of the UPR^mt^ ([@R59]). We therefore included SOD1 and also found it upregulated in ROS+ cells ([Figure 1G](#F1){ref-type="fig"}).

To test if mitohormesis was occurring, we assessed mitochondrial ROS levels following *ex vivo* expansion ([Figure 1H](#F1){ref-type="fig"}). Consistent with persistent activation of cytoprotective mechanisms by mitohormesis, we found the original ROS+ subpopulation had significantly lower levels of ROS ([Figure 1H](#F1){ref-type="fig"}), suggesting that this subpopulation is resistant to oxidative stress from *ex vivo* growth. We then isolated the ROS− portion of the original subpopulations by FACS to query activation of the UPR^mt^ under lower levels of oxidative stress ([Figure 1H](#F1){ref-type="fig"}). We found that the original ROS+ subpopulation still had enhanced activation of the UPR^mt^ ([Figure 1I](#F1){ref-type="fig"}). This observation supports the conclusion that oxidative stress in primary tumors induces mitohormesis in a population of cells. To functionally demonstrate the consequence of mitohormesis, we subjected the original ROS− and ROS+ subpopulations to an oxidative stress challenge using menadione--a redox cycling compound that promotes mitochondrial ROS production and mitochondrial stress ([@R12]). We found that the ROS+ subpopulation was significantly more resistant to cell death by menadione than its ROS− counterpart ([Figure 1J](#F1){ref-type="fig"}). Taken together, these results suggest that cells primed by mitohormesis maintain activation of the UPR^mt^ and are resistant to subsequent stress.

After finding different UPR^mt^ subpopulations within the primary tumor, we sought to assess UPR^mt^ activation *in situ* and ask if metastatic lesions are enriched for the UPR^mt^. Using *MMTV-rtTA/TetO-NeuNT* mice that develop spontaneous lung metastases ([Figure S1C](#SD1){ref-type="supplementary-material"}), we first established that doxycycline alone does not activate the UPR^mt^ ([Figures S1D](#SD1){ref-type="supplementary-material"}--[S1F](#SD1){ref-type="supplementary-material"}; see [STAR Methods](#S7){ref-type="sec"}). We then used immunohistochemistry (IHC) to monitor UPR^mt^ activation in primary tumors and lung metastases of these mice. In primary tumors, we found heterogeneous staining of all UPR^mt^ markers ([Figure 2A](#F2){ref-type="fig"}). This suggests that the UPR^mt^ is focally activated in primary tumors under endogenous stress. Further, we found that all markers of the UPR^mt^ except FOXO3a were increased in lung metastases compared with primary tumors ([Figure 2B](#F2){ref-type="fig"}), indicating *in vivo* that metastatic cells activate the UPR^mt^. Using overlaid serial sections stained by IHC, we found that all markers of the UPR^mt^ co-localize in primary tumors ([Figure 2C](#F2){ref-type="fig"}) and metastatic lesions ([Figure 2D](#F2){ref-type="fig"}). Collectively, these results demonstrate that mitohormesis is observed in cells under endogenous stress, leading to UPR^mt^ activation and a selective advantage to metastasize.

Endogenous Mitochondrial Stress in Human Breast Cancer Cell Lines Activates the UPR^mt^ and Increases Invasion {#S4}
--------------------------------------------------------------------------------------------------------------

To determine if mitohormesis and its contribution to metastasis occurred in human breast cancer, we used MCF7 and MDA-MB-231 cells in which we previously characterized the UPR^mt^ ([@R37]). Having established that endogenous mitohormesis primed a subpopulation of cancer cells *in vivo* to become more invasive, we hypothesized that the invasive subpopulation of a given cell line should have increased UPR^mt^ activation. To test this possibility, we performed a transwell invasion assay with MCF7 cells and isolated the invasive subpopulation, MCF7 iteration 1 (I1) ([Figure 3A](#F3){ref-type="fig"}). As expected, MCF7 I1 cells were more invasive than the parental ([Figure 3B](#F3){ref-type="fig"}). When mitochondrial ROS levels were compared, MCF7 I1 cells had less than the parental, consistent with mitohormesis ([Figure 3C](#F3){ref-type="fig"}). Importantly, MCF7 I1 cells had more UPR^mt^ activation ([Figure 3D](#F3){ref-type="fig"}). We also analyzed levels of NRF2, as it is a master transcription factor for antioxidant genes and binds to the promoter of SIRT3 ([@R15]; [@R30]; [@R64]; [@R74]). Compared with parental, MCF7 I1 had more NRF2 ([Figure S2A](#SD1){ref-type="supplementary-material"}).

Having demonstrated low and high ROS subpopulations in primary tumors, we asked if this was true in MCF7 cells. We identified and isolated a small ROS+ subpopulation of MCF7 by FACS ([Figure 3E](#F3){ref-type="fig"}). We found that the ROS+ subpopulation was significantly more invasive than the parental ([Figure 3F](#F3){ref-type="fig"}) and had increased activation of the UPR^mt-SIRT3^ but not HSP60 or SOD1 ([Figure 3G](#F3){ref-type="fig"}).

To further test these observations, we repeated the same analyses in invasive, UPR^mt-SIRT3^ positive MDA-MB-231 cells. Two consecutive rounds of invasion were used to generate MDA-MB-231 I1 and I2 cells ([Figure 3H](#F3){ref-type="fig"}). We found that MDA-MB-231 I1 and I2 were progressively more invasive than the parental ([Figure 3I](#F3){ref-type="fig"}) and had decreased ROS ([Figure 3J](#F3){ref-type="fig"}). Consistent with mitohormesis, MDA-MB-231 I1 and I2 showed successive increases in the UPR^mt^ ([Figure 3K](#F3){ref-type="fig"}). We also queried NRF2 levels and observed cumulative increases in the invasive sub-populations ([Figure S2B](#SD1){ref-type="supplementary-material"}). When we isolated the ROS+ of MDA-MB-231 cells by FACS ([Figure 3L](#F3){ref-type="fig"}), we again found that the ROS+ subpopulation was more invasive than the parental ([Figure3M](#F3){ref-type="fig"}). Additionally, ROS+ MDA-MB-231 had enhanced UPR^mt^ activation compared with the parental, except for HSP60 ([Figure 3N](#F3){ref-type="fig"}). To test if mitohormetically primed cells are resistant to oxidative stress, we again used menadione. As before ([Figure 1J](#F1){ref-type="fig"}), we found that MDA-MB-231 I1, I2, and ROS+ cells were more resistant to cell death than the parental ([Figure S2C](#SD1){ref-type="supplementary-material"}).

To address causality between ROS reduction by UPR^mt^ activation and the invasive phenotype, we treated parental MDA-MB-231 with the antioxidant *N*-acetyl-[l]{.smallcaps}-cysteine (NAC) and compared invasion with parental and I2 cells without NAC ([Figure S2D](#SD1){ref-type="supplementary-material"}). We found that treatment with NAC significantly increased invasion of MDA-MB-231 parental cells in comparison to the control but not to the same level as I2 cells ([Figure S2D](#SD1){ref-type="supplementary-material"}). We conclude that reduction of ROS by UPR^mt^ activation promotes invasion but cannot alone explain the phenotype. We therefore used gamitrinib-triphenylphosphonium (G-TPP), a compound shown to activate the UPR^mt^ ([@R34]; [@R59]; [@R65]) to exogenously activate the UPR^mt^ and analyze invasion capacity. When treated with 5 μM G-TPP, MDA-MB-231 showed robust activation of all UPR^mt^ markers ([Figure S2E](#SD1){ref-type="supplementary-material"}) and enhanced invasion capacity ([Figure S2F](#SD1){ref-type="supplementary-material"}) compared with DMSO control. These results demonstrate that UPR^mt^ activation promotes invasion.

To address causality between UPR^mt^ activation and invasion mechanistically, we performed small interfering RNA (siRNA) knockdown of SIRT3 in MDA-MB-231. SIRT3 knockdown leads to a subsequent decrease of UPR^mt-SIRT3^ markers (FOXO3a, SOD2, NRF1) but not SOD1 or HSP60 ([Figures 3O](#F3){ref-type="fig"} and [3P](#F3){ref-type="fig"}). Interestingly, SIRT3 knockdown significantly increased LC3, suggesting a potential non-SIRT3-mediated mechanism of upregulation to maintain viability after UPR^mt-SIRT3^ knockdown ([Figures 3O](#F3){ref-type="fig"} and [3P](#F3){ref-type="fig"}). Importantly, transwell assays of MDA-MB-231 treated with siSIRT3 or non-targeting control revealed that SIRT3 knockdown significantly reduced invasion ([Figure 3Q](#F3){ref-type="fig"}). The inhibitory effect of SIRT3 knockdown on invasion was validated using a second siRNA ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}). Additionally, SIRT3 knockdown did not affect proliferation ([Figure S2C](#SD1){ref-type="supplementary-material"}) or viability ([Figure S2D](#SD1){ref-type="supplementary-material"}), demonstrating a specific effect on invasion. To assess the role of SIRT3 in metastasis *in vivo*, we generated stable control (shScrambled) and SIRT3 knockout (shSIRT3-345 and shSIRT3-752) MDA-MB-231 cells ([Figure 3R](#F3){ref-type="fig"}). Western blotting of these cells confirmed near complete loss of SIRT3 in shSIRT3-345 and shSIRT3-752 compared to shScrambled and ubiquitous GFP expression in all three lines ([Figure 3R](#F3){ref-type="fig"}). We queried *in vitro* invasion capacity of these cells and found that SIRT3 loss reduced invasion capacity ([Figure S2K](#SD1){ref-type="supplementary-material"}) without impacting *in vitro* proliferation ([Figure S2L](#SD1){ref-type="supplementary-material"}), as in our siRNA experiments ([Figures 3Q](#F3){ref-type="fig"} and [S2I](#SD1){ref-type="supplementary-material"}). We then performed tail vein injections with these cells and harvested 4 weeks later. Two-photon microscopy was used on freshly excised lungs to visualize GFP+ metastases. While disseminated cells could be identified in all three experimental groups, markedly larger metastatic lesions were detected in shScrambled compared with either shSIRT3 group ([Figures 3S](#F3){ref-type="fig"} and [S2M](#SD1){ref-type="supplementary-material"}). These results indicate that SIRT3 is necessary for overt lung metastasis formation. Whole lung sections were stained by immunofluorescence (IF) for GFP to quantify single disseminated cells, clusters, and micro-metastases. As observed by two-photon microscopy, the shScrambled group had appreciably more multi-cellular lesions than either shSIRT3 group by IF ([Figures 3T](#F3){ref-type="fig"} and [S2N](#SD1){ref-type="supplementary-material"}). Importantly, we found significantly more metastatic lesions irrespective of size in shScrambled mice compared with shSIRT3-345 or shSIRT3-752 ([Figures 3T](#F3){ref-type="fig"} and [S2N](#SD1){ref-type="supplementary-material"}). This suggests that SIRT3 promotes the invasion and extravasation capacity of metastatic breast cancer cells at secondary organs. Taken together, these results demonstrate that SIRT3 is necessary for multiple steps of the metastatic cascade.

UPR^mt^ Gene Signature Identifies Breast Cancer Patients with Worse Prognoses and Mitohormetic Transcriptional Profiles {#S5}
-----------------------------------------------------------------------------------------------------------------------

To address the translational relevance of our findings to patients, we took advantage of publicly available primary breast cancer expression datasets. In a cohort of 1809 patients ([@R28]), we extracted expression levels of *SIRT3, FOXO3a, SOD2, SOD1, LC3B, NRF1,* and *HSP60* and computed an average UPR^mt^ expression score per patient ([Figure 4A](#F4){ref-type="fig"}). We found a clear subset of patients with higher expression of all markers and called them UPR^mt-HIGH^ ([Figure 4A](#F4){ref-type="fig"}). Treating URP^mt^ score as a categorical value, we found a significant association between UPR^mt-HIGH^ and estrogen receptor (ER)-negative disease ([Figure 4A](#F4){ref-type="fig"}). This association was also significant when UPR^mt^ score was treated as a continuous variable ([Figure S3A](#SD1){ref-type="supplementary-material"}). UPR^mt^ score was also calculated in the The Cancer Genome Atlas (TCGA) breast cancer cohort and again showed a significant association between ER-negative disease and elevated UPR^mt^ ([Figure S3B](#SD1){ref-type="supplementary-material"}). The molecular classifications in the TCGA cohort enabled comparison of UPR^mt^ among PAM50 intrinsic subtypes ([Figure S3C](#SD1){ref-type="supplementary-material"}). We found that the UPR^mt^ scores were significantly different between breast cancer subtypes, with basal-like and *HER2*-Enriched having significantly higher levels than luminal A and luminal B ([Figure S3C](#SD1){ref-type="supplementary-material"}).

We then assessed the impact of UPR^mt^ expression on outcomes using the larger Kaplan-Meier (KM) plotter cohort ([@R42]). Alone, the individual UPR^mt^ genes had mixed prognostic value ([Figures S3D](#SD1){ref-type="supplementary-material"}--[S3J](#SD1){ref-type="supplementary-material"}). A multigene classifier of these 7 genes was used to compare clinical outcomes between UPR^mt-HIGH^ and UPR^mt-LOW^ patients. We found that UPR^mt-HIGH^ patients had significantly worse overall survival ([Figure 4B](#F4){ref-type="fig"}), relapse-free survival ([Figure 4C](#F4){ref-type="fig"}), and distant metastasis--free survival ([Figure 4D](#F4){ref-type="fig"}) compared with UPR^mt-LOW^ patients. Even in lymph node-positive patients, a population which is at significant increased risk of metastatic relapse, UPR^mt-HIGH^ patients had significantly worse distant metastasis-free survival ([Figure 4E](#F4){ref-type="fig"}).

To further understand differences between UPR^mt-HIGH^ and UPR^mt-LOW^ patients, we compared global gene expression between the groups. Differential gene expression analysis between UPR^mt-HIGH^ and UPR^mt-LOW^ patients identified 141 genes with a log2 fold change ≥ ±0.6 and a false discovery rate \<0.05 ([Figure 4F](#F4){ref-type="fig"}; [Tables S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}).

Transcripts significantly upregulated in UPR^mt-HIGH^ patient tumors included metalloproteases (*MMP1, ADAM15, MM7, MMP12*) and immune-related genes, such as *MARCO* ([Figure 4F](#F4){ref-type="fig"}; [Tables S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}). *MARCO* identifies a subset of tumor-associated macrophages that promotes tumor growth and metastatic dissemination ([@R24]). Of interest, PDK1 was significantly increased in UPR^mt-HIGH^ patients ([Figure 4F](#F4){ref-type="fig"}). *PDK1* was also upregulated in the livers of mitohormetically primed iSOD2-KD mice ([@R12]). Transcripts significantly downregulated in UPR^mt-HIGH^ patient tumors include the metabolic enzyme *MGAM*, and *PTHLH*, which is implicated in epithelial-mesenychmal interactions in the developing mammary gland ([Figure 4F](#F4){ref-type="fig"}; [Tables S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}).

To understand the gene expression programs differing between UPR^mt-HIGH^ and UPR^mt-LOW^ patients, we performed pre-ranked gene set enrichment analysis (GSEA) ([Table S3](#SD4){ref-type="supplementary-material"}; [@R79]). We found that cholesterol homeostasis, cell cycle, and peroxisome proliferator-activated receptor (PPAR) signaling were positively enriched in UPR^mt-HIGH^ patients ([Figure 4G](#F4){ref-type="fig"}; [Table S4](#SD5){ref-type="supplementary-material"}). PPAR signaling was identified as the defining transcriptional signature of mitohormetically primed iSOD2-KD mice ([@R12]). In addition, mTORC1 signaling and glycine, serine, and threonine metabolism were positively enriched in UPR^mt-HIGH^ patients, in agreement with data that these pathways are activated by mitochondrial stress ([@R68]). Interestingly, it has been shown that mTORC1 regulates SOD1 activity ([@R82]) and HSP60 as part of the mitochondrial integrated stress response (ISRmt) ([@R39]). This highlights the integrated nature of mitochondrial stress responses and substantiates the UPR^mt^ as a complex network of signaling axes. Importantly, metastasis, angiogenesis, and cell migration gene sets were positively enriched in UPR^mt-HIGH^ patients ([Figure 4G](#F4){ref-type="fig"}; [Table S4](#SD5){ref-type="supplementary-material"}). Innate immunity and inflammation-related gene sets were also positively enriched, in agreement with observations in *C. elegans* that linked the UPR^mt^ to innate immunity ([@R67]) ([Figure 4G](#F4){ref-type="fig"}; [Table S4](#SD5){ref-type="supplementary-material"}).

Conversely, we found processes related to protein production, such as translational elongation and the ribosome, negatively enriched in UPR^mt-HIGH^ patients ([Figure 4G](#F4){ref-type="fig"}; [Table S5](#SD6){ref-type="supplementary-material"}). This is consistent with work showing translational inhibition in response to mitochondrial stress ([@R59]; [@R73]; [@R93]).

Taken together, these results demonstrate that UPR^mt^ activation is observed in patient samples and is significantly associated with worse clinical outcomes including metastasis. Further, we found that the global gene expression of UPR^mt-HIGH^ patients is indicative of mitohormetic priming and persistent cytoprotective mechanisms.

DISCUSSION {#S6}
==========

The mitochondria of cancer cells show profound reprogramming and elevated ROS. ROS levels in cancer must be maintained to ensure viability. The ability of ROS manipulation to impact tumor biology is supported by studies demonstrating that antioxidants promote cancer growth and metastasis ([@R4]; [@R43]; [@R75]).

Here, we provide evidence that mitohormesis, a phenomenon normally associated with health and longevity, is perniciously used by cancer cells to promote tumor progression. Mitohormesis in cancer cells results in persistent activation of the UPR^mt^ and reduction in oxidative stress. Resultantly, mitohormetically primed cancer cells are more metastatic. The molecular mechanisms underlying mitohormetic activation and UPR^mt^ persistence in cancer remains elusive. A likely possibility is that epigenetic regulation is involved, as shown in *C. elegans* ([@R52]; [@R54]; [@R81]). Future work will address such outstanding questions.

Our findings indicate that elevated UPR^mt^ in patients results in significantly worse survival. Analysis of the transcriptomes of UPR^mt-HIGH^ patients shows simultaneous activation of prometastatic programs and the global cytoprotective effects of mitohormesis. Our patient-derived UPR^mt^ signature showed significant overlap with mito-protective pathways obtained from *in vitro* or genetic manipulations of mitochondrial stress ([@R7]; [@R59]; [@R67]; [@R68]; [@R81]). Of note, translational repression was strongly affected by the UPR^mt^ classifer, consistent with reports characterizing exogenous UPR^mt^ induction *in vitro* ([@R59]; [@R68]). Mitochondria can influence innate immunity through the cytoplasmic release of mtDNA ([@R91]; [@R92]). Interestingly, we see significant enrichment of innate immunity gene sets in UPR^mt-HIGH^ patients suggesting a possible role for mitohormesis in shaping the tumor microenvironment. Several neurodegenerative gene sets were negatively enriched in UPR^mt-HIGH^ patients. This is consistent with our work showing that UPR^mt^ activation delayed symptom onset in a familial amyotrophic lateral sclerosis (ALS) mouse model ([@R71]). This observation suggests that mitohormesis, which we show promotes tumor progression, is predicted to oppose neurodegeneration.

In the context of cancer biology, our results are also in agreement with numerous studies reporting mitochondrial changes in recurrent tumors and circulating cancer cells. These changes included oxidative phosphorylation, mitochondrial biogenesis, and SOD2 and PGC-1α upregulation, although a unifying mechanism was not identified ([@R33]; [@R44]; [@R85]). The results of our study suggest that activation of the UPR^mt-SIRT3^ mechanistically underlies these observations.

This possibility is further supported by the fact that SIRT3 is a common denominator linking mitochondrial biogenesis, PGC1α, and SOD2. SIRT3 directly controls the activity of SOD2 through deacetylation ([@R51]; [@R80]). PGC1-α, in complex with ERRα regulates several genes involved in mitochondrial biogenesis as well as SOD2 and SIRT3 ([@R41]; [@R25]). SIRT3 indirectly regulates PGC1-α through AMPK signaling, which promotes CREB phosphorylation and PGC1α expression ([@R78]). Therefore, SIRT3 and PGC1α crosstalk establishes a positive feedback loop to regulate mitochondrial biogenesis and antioxidant defenses. In this study, the transcriptional signature of UPR^mtHIGH^ patients was significantly enriched for PPAR signaling, of which PGC1α is a key component. Notably, the PPAR signaling pathway and PGC1α were key differences seen in mitohormetically primed mice ([@R12]).

In cancer biology, SIRT3 has been reported to act as an oncogene ([@R1]; [@R10]; [@R11]; [@R13]; [@R23]; [@R47]; [@R65]; [@R89]; [@R90]) and a tumor suppressor ([@R2]; [@R16]; [@R18]; [@R21]; [@R40]; [@R47]; [@R88]; [@R90]; [@R95]; [@R97]). This discrepancy suggests that the function of SIRT3 in cancer is context dependent. Loss of *SIRT3* during tumor formation leads to increased ROS levels and promotes mitochondrial reprogramming ([@R21]). Importantly, *SIRT3* loss is heterozygous, suggesting selective pressure to maintain an intact copy of the gene ([@R21]). When the prognostic value of individual UPR^mt^ genes was analyzed, elevated SIRT3 was associated with better relapse-free survival ([Figure S3F](#SD1){ref-type="supplementary-material"}), in agreement with a recent report ([@R46]). This observation is consistent with a study demonstrating that SIRT3 overexpression in MDA-MB-231 cells delays tumor growth in xenografts ([@R27]). It is important to note that this overexpression far exceeds the endogenous levels found in invasive cells, such as MDA-MB-231. The same group also demonstrated that SIRT3 is downregulated in the invasive front of MCF10A cells ([@R46]). To reconcile these observations, we propose the following model ([Figure S4](#SD1){ref-type="supplementary-material"}). In normal cells, SIRT3 levels are highest. This is supported by the observation that MCF10A cells have significantly higher SIRT3 levels than breast cancer cells lines ([@R65]). During transformation, heterozygous *SIRT3* loss increases ROS, which stabilizes HIF1α and produces a glycolytic switch ([@R6]; [@R8], [@R9]; [@R21]; [@R29]). During tumor progression, however, the retained *SIRT3* allele is used to promote invasion and metastasis.

In conclusion, we demonstrate that endogenous mitohormesis leads to persistent activation of the UPR^mt^ in a subset of cancer cells. Consistent with the pro-longevity effect of mitohormesis, its activation leads to global changes in cytoprotective mechanisms, which results in resistance to subsequent stress. In the context of cancer, however, mitohormesis promotes metastatic disease progression.

STAR★METHODS {#S7}
============

Detailed methods are provided in the online version of this paper and include the following:

CONTACT FOR REAGENT AND RESOURCE SHARING {#S8}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by Doris Germain, DG (<doris.germain@mssm.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S9}
--------------------------------------

### Cell Culture {#S10}

MDA-MB-231 and MCF7 cells, and their respective sub-lines were cultured in DMEM media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). LentiX-293T cells (Takara Clonetech) were cultured in DMEM media supplemented with 10% FBS and 1% P/S. Cells derived from *MMTV-rtTA/TetO-NeuNT* mammary tumors were grown in DMEM / F12 (50/50) supplemented with 10% FBS, 1% P/S, 25 ng/mL Hydrocortisone, 0.25 μg/mL Amphotericin B, and 2 μg/mL Doxycycline and cultured on collagen coated plates (50 μg/mL Collagen 1 rat tail in 0.01M HCL).

### Animals {#S11}

All animal experiments were performed under an IUCAC approved protocol. *MMTV-rtTA/TetO-NeuNT* mice were originally generated and kindly provided by Lewis Chodosh. Genotypes of mice were confirmed using the following primers: rtTA (5′-TGCCGCCAT TATTACGACAAGC-3′; 5′-ACCGTACTCGTCAATTCCAAGGG-3′) and Neu: (5′-TTTCCTGCAGCAGCCTACGC-3′, 5′-CGGAACCCA CATCAGGCC-3′). Experimental *MMTV-rtTA/TetO-NeuNT* were 12-week-old females. Non-transgenic FVBN and C57BL/6N were also used in this study. Experimental FVBN mice were 8-week-old females. Experimental C57BL/6N mice were 8-week-old males. Female Athymic Nude-*Foxn1*^*nu*^ mice 9 or 12 weeks of age were used for tail vein injection experiments. All mice were housed in vivariums at Mount Sinai with *ad libitium* access to food and water.

METHOD DETAILS {#S12}
--------------

### siRNA Transfection {#S13}

Transfections were performed for 72 hours on cells seeded in antibiotic-free medium using Lipofectamine RNAi Max (Invitrogen 13778-100) and Opti-MEM (GIBCO) following manufacturer recommendations. Transfections were performed with non-targeting DsiNC1 (IDT \#51-01-14-03) or SIRT3 targeting siRNA: siSIRT3 \#1 (5'-GCCCAACGUCACUCACUACTT --3′, 5′-GUAGUGAGUGAC GUUGGGCTT-'3; GeneLink) and siSIRT3 \#2 (5'-ACUCCCAUUCUUCUUUCACTT-3′, 5′- GUGAAAGAAGAAUGGGAGUTT-3′; GeneLink). Percent of cells alive and total cell number were determined using the Countess automated cell counter and tryphan blue (Invitrogen) on MDA-MB-231 cells treated with siNC1, siSIRT3 \#1, or siSIRT3 \#2 after 72 hours transfection to determine viability and *in vitro* proliferation ([Figure S2](#SD1){ref-type="supplementary-material"}).

### Generation of stable shRNA cell lines {#S14}

A pre-designed shRNA vector set was purchased from Biosettia with shRNAs designed against *SIRT3* (Gene ID 23410; Accession NM_001017524.2) in the *pLV-H1-CMV-Green* plasmid (Biosettia \#SORT-B01). NEB stable competent E. Coli cells (New England BioLabs \#C3040) were transformed by heat shock with plasmids obtained from Biosettia. Transformed colonies were picked and expanded under antibiotic selection. Plasmids were prepared from bacterial cultures by Maxiprep (QIAGEN \#12165). OptiMEM (GIBCO) and Lipofectamine 2000 (Invitrogen \#11668019) were used to transfect 9 μg of *pLV-H1-CMV-Green* plasmid, 6 μg *psPAX2* plasmid (Addgene \#12260), and 3 μg *pMD2.G* plasmid (Addgene \#12259) into LentiX 293T packaging cells in antibiotic free medium. *pMD2.G* and *psPAX2* plasmids were generous gifts from Didier Trono. Lentivirus containing media was then collected, filtered and used with polybrene to infect target MDA-MB-231 Parental cells. Transduced cells were selected for using fluorescence associated cell sorting (FACS) to generate stable shRNA cell lines.

### Transwell Invasion Assays {#S15}

Cells were trypsinized and collected in respective serum-free media (see [Cell Culture](#S10){ref-type="sec"}) and pelleted at 2500 rpm for 5 minutes. Cells were resuspended in respective serum-free media and counted using the Countess automated cell counter and tryphan blue (Invitrogen). Equal cell numbers were seeded in respective serum-free media on 8 μm pore size cell culture inserts for 24-well plates (Corning). Prior to seeding cell seeding, cell culture inserts were coated with growth factor reduced matrigel (GIBCO) diluted 1:100 in PBS that was incubated at room temperature for 2 hours and removed. Respective media with 10% FBS was used in the lower chamber and assays were performed for time frames indicated (see Figures) in a tissue culture incubator. Following incubation, invaded cells were fixed, stained using the Hema 3 Manual Staining Stat Pack according to manufacturer's guidelines (Thermo Fisher Scientific), and placed on glass slides with mounting media (Permount). To generate invasive clones of MCF7 and MDA-MB-231 cells, the protocol outlined above was followed except 8 μm pore size cell culture inserts for 6-well plates (Corning) were used and invaded cells were detached by trypsin and subsequently cultured.

### Western Blotting {#S16}

Cells, washed with PBS, or pulverized flash frozen tissue was lysed in cold NP-40 lysis buffer with protease inhibitors (50 mM Tris, pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 50 mM NaF, 0.2 mM Na~3~ VO~4~, 1 g/ml leupeptin, 1 g/ml pepstatin, 100 g/ml phenylmethylsulfonyl fluoride), sonicated for 5 s at 20% amplitude, and centrifuged at 14,000 rpm for 20 minutes at 4°C. Protein concentrations of lysates were assayed using the Bradford method (Bio-Rad Protein Assay). Equal amounts of protein were separated by SDS-PAGE electrophoresis and transferred to nitrocellulose membrane (GE Healthcare). Following blocking, membranes were probed with the following primary antibodies overnight at 4°C: SIRT3 (Cell Signaling 2627S), SIRT3 (EMD Millipore 07-1596), HSP60 (BD Transduction 611563), ATF5 (abcam ab184923), NRF1 (abcam ab55744), ClpP (abcam ab 124822), SOD1 (Santa Cruz sc-11407), FOXO3a (Cell Signaling 2497S), Actin (EMB Millipore MAB1501R), SOD2 (EMB Millipore 06-984), LC3 (MBL International PM036), SDHA (abcam ab14715), MTCO1 (abcam ab45918), GFP (Santa Cruz sc-9996), NRF2 (cell Signaling 12721). Blots were then probed with horseradish peroxidase conjugated anti-mouse (Jackson ImmunoResearch or KwikQuant) or anti-rabbit secondary antibodies (Thermo Fisher Scientific or KwikQuant) and detected using enhanced chemiluminescence (GE Healthcare or KwikQuant).

### Flow Cytometry and Fluorescence Associated Cell Sorting (FACS) {#S17}

Cells growing in culture were detached with trypsin, collected in respective media, and centrifuged to pellet cells. Cells were then washed in PBS and finally resuspended in 0.5% Bovine Serum Albumin (BSA) in Hank's Balanced Salt Solution (HBSS). Appropriate volume of freshly made 5 mM stock of MitoSOX Red (Thermo Fisher Scientific M36008) was added to cells in 0.5% BSA HBSS to yield final staining concentration of 5 μM. Staining was perfomed for 30 minutes at 37°C in the dark. Following staining, cells were pelleted by centrifugation, washed in 0.5% BSA HBSS, and resuspended in 0.5% BSA HBSS and passed through a single cell strainer before flow cytometry or FACS. Using the BD FACSAria II and BD FACSDiva software, samples were excited and captured at wavelengths consentient with the fluorescent spectrum of MitoSox. When sorting was performed, noted populations were selected and sorted for subsequent analyses or culture.

Primary mammary tumors from *MMTV-rtTA/TetO-NeuNT* mice were extracted from euthanized animals and placed in DMEM / F12 (50/50) supplemented with 25 ng/mL Hydrocortisone, 0.25 μg/mL Amphotericin B, and 2 μg/mL Doxycycline and brought into a tissue culture hood. Tumors were mechanically cut and digested using scalpels and the homogenized tumor was placed in a 50 mL falcon tube and filled with supplemented DMEM/F12 (50/50) media. Tumor homogenate and media was mixed by repeated inversion and centrifuged at 900 rpm to separate pelleted cells from fat and debris. Pelleted cells were washed in PBS and then resuspended in red blood cell (RBC) lysis buffer and mixed gently for 1-2 minutes. Supplemented media was then added to cells in RBC lysis buffer and centrifuged at 200-500 g for 7 minutes. Pellet was resuspended in supplemented media plus 1 mg/mL collagenase (Sigma-Aldrich C9891). This was incubated at 37°C for 30 minutes with pipetting performed twice during the incubation to aid in digestion. Following incubation, the solution was briefly vortexed and stood upright for 1-2 minutes to allow large chunks to settle. The supernatant was collected and centrifuged at 900 rpm for 5 minutes. The pellet was then resuspended in supplemented media and passed through a 70 μm nylon strainer to achieve single cell suspension. Cells were then pelleted, washed with PBS, and resuspended in 0.5% BSA HBSS. Staining and flow cytometry/FACS was then performed as above.

### Animal Experiments: MMTV-rtTA/TetO-NeuNT mice {#S18}

12-week-old female *MMTV-rtTA/TetO-NeuNT* were given doxycycline in drinking water (Sigma Aldrich) at a concentration of 0.75 g/L for 7 weeks or 1.5 g/L for 12 weeks. Doxycycline water was changed biweekly. At euthanasia, primary tumors and lungs were collected and formalin fixed, flash frozen, and/or processed for FACS.

### Animal Experiments: Doxycycline treatment, analysis of UPR^mt^ {#S19}

As doxycycline has been reported to inhibit mitochondrial translation and induce mitochondrial stress ([@R58]), we first tested whether, doxycycline alone induces the UPR^mt^ in non-transgenic mice treated with doxycycline. We found no changes in markers of either the UPR^mt-SIRT3^ or URP^mt-CHOP^ ([Figure S1D](#SD1){ref-type="supplementary-material"}). As the ratio of MTCO1 to SDHA has been used previously as a marker of mitochondrial stress and imbalance between the mitochondria and nuclear genome ([@R58]), this ratio was also tested. No difference was observed in either the mammary gland ([Figure S1D](#SD1){ref-type="supplementary-material"}) or the liver ([Figure S1E](#SD1){ref-type="supplementary-material"}). As this result is in contrast to the reported effect of doxycycline ([@R58]), we repeated the experiment using the same gender, strain, and experimental conditions as the published study ([@R58]). Using these conditions, we found that doxycycline promotes mitonuclear protein imbalance as measured by the ratio of MTCO1 to SDHA, ([Figure S1E](#SD1){ref-type="supplementary-material"}) but did not lead to a concomitant activation of either the UPR^mt-SIRT3^ or UPR^mt-CHOP^ ([Figure S1E](#SD1){ref-type="supplementary-material"}). This observation is consistent with a more recent report from the Auwerx group showing that doxycycline does not activate canonical UPR^mt^ pathways([@R68]). It also suggests that the effect of doxycycline varies between mouse strains and/or gender.

8-week-old female FVBN mice were given doxycycline (Sigma Aldrich) at a concentration of 1.5 g/L in drinking water for 30 days. Doxycycline water was changed biweekly. At euthanasia, livers and mammary glands were flash frozen for subsequent analysis. 8-week-old male C57BL/6N mice were given amoxicillin (Sigma Aldrich) at 50/mg/kg/day for 15 days or 500mg/kg/day doxycycline for 15 or 30 days in 50 g/L sucrose water. Both amoxicillin and doxycycline sucrose water was changed every 48 hours. At euthanasia, livers were flash frozen for subsequent analysis.

### Animal Experiments: Tail Vein Injections {#S20}

For experiments in [Figure 1](#F1){ref-type="fig"}, 12-week-old female Athymic Nude-*Foxn1*^*nu*^ mice were given doxycycline at a concentration of 1.5 g/L in drinking water 2 weeks prior to tail vein injection and this was continued throughout the experiment. Doxycycline water was changed biweekly. FACS sorted primary tumor subpopulations (ROS- or ROS+) expanded *ex vivo* were used for tail vein injection. Prior to tail vein injection, the bioluminescence of ROS− and ROS+ subpopulations was confirmed *in vitro* and was found to be insignificantly different between the two. 5×10^5^ cells in 100 μL PBS was injected into the tail vein of each mouse. Five mice per group were injected.

For experiments in [Figure 3](#F3){ref-type="fig"}, 9-week-old female Athymic Nude-Foxn1^nu^ mice were used for tail injections. 1×10^6^ cells in 100 uL PBS supplemented with 1% FBS were injected into the tail vein of each mouse. Five mice per group were injected.

### Histology and Immunohistochemistry (IHC) {#S21}

Tissue was fixed in 10% formalin (Thermo Fisher Scientific) and then processed and paraffin embedded for sectioning by the Biorepository Core Facility at Mount Sinai. Hematoxylin and eosin (H&E) or unstained paraffin embedded slides were obtained the from the core facility. Serial 5 μm sections were used for all IHC staining. Briefly, sections were deparrafinized and rehydrated in xylene followed by decreasing alcohol gradients. Antigen retrieval was performed for 30 minutes at 95°C in either citrate buffer pH 6 or 10 mM TRIS 1 mM EDTA pH 9. Following antigen retrieval, endogenous peroxidase activity was quenched using Dako Dual Endogenous Enzyme Block (\#S20003) followed by serum blocking (MP Biomedicals Normal Antibody Diluent \#98063) at room temperature. Primary antibody staining was performed at room temperature or 4°C for an optimized length of time. Secondary antibody staining with either Biotynlated Anti-Rabbit (Jackson ImmunoResearch \#711-065-152) or Biotynlated Anti-Mouse (Jackson ImmunoResearch \#115-065-205) diluted in TBS was incubated at room temperature for an optimized length of time. Streptavidin-HRP (Vector Labs \#SA-5004) was diluted in TBS and incubated for 30 minutes at room temperature. All washes were performed with TBS with 0.04% Tween 20. Antigen detection was performed with freshly prepared AEC Solution (Vector Labs \#SK-4200) according to manufacturer guidelines for an optimized length of time. Sections were counterstained with hematoxylin, sufficiently rinsed in water, and mounted in Vectamount aqueous mounting media (Vector Labs \#H-5501). For specific conditions used for each antigen staining, see [Table S6](#SD1){ref-type="supplementary-material"}.

Sequentially sectioned (5 μm apart) primary tumors and lungs were stained with all indicated antibodies and matching regions of interest were imaged at the same magnification using a Zeiss AX10 light microscope. These images were imported into Adobe Photoshop individually and a layer encompassing all positive staining created. This layer was pseduocolored and saved alone. Multiple psuedocolored layers from different stainings were superimposed on one another after proper alignment. These overlays were saved and displayed on a black background to generate the images seen in [Figure 2](#F2){ref-type="fig"}.

### Immunofluorescence {#S22}

Sections were deparaffinized and rehydrated in xylene followed by decreasing alcohol gradients. Antigen retrieval was performed in citrate buffer pH 6 for 20 minutes in the microwave. Blocking was performed with 10% serum in 0.5% Tween-20 PBS for 2 hours at room temperature. Primary antibody (GFP; Santa Cruz sc-9996) staining was performed overnight at 4°C at a concentration of 1:100 in 1% serum 0.5% Tween-20 PBS. Secondary antibody (Alexa Flour 488 goat anti-mouse; Invitrogen \#A11001) staining was performed for 2 hours at roomperature at a concentration of 1:250 in 1% serum 0.5% Tween-20 PBS. Finally, sections were stained with DAPi for 20 minutes at room temperature prior to mounting with Flouromount-G (Southern Biotech). All washes were performed in 0.5% Tween-20 PBS. Sections stained following the protocol above with the exception of no primary antibody were used as negative controls. Metastatic lesions were visualized, counted, and imaged using a Leica DM5500 B upright automated microscope.

### Multiphoton Microscopy {#S23}

Freshly excised lungs from mice used in [Figure 3](#F3){ref-type="fig"} were imaged using an Olympus FV1000 multiphoton microscope with an Olympus 25X 1.05 NA water immersion objective. As previously described ([@R62]), a Coherent Chameleon Vision II laser was used at 880 nm to excite GFP. Collagen was visualized by second harmonic generation. 512 × 512 images were taken at 12.5 μs/pixel with a Z step-size of 5 μm using a Kalman filter. For all images, the RFP channel was also captured to rule out artifactual autofluorescence.

### Bioluminescence Imaging {#S24}

Given that the *MMTV-rtTA/TetO-NeuNT* mice have an IRES-Firefly Luciferase sequence downstream of the Tet-inducible *NeuNT,* we performed whole body bioluminescence imaging on anthymic nude mice that were tail vein injected with isolated *MMTV-rtTA/TetO-NeuNT* primary tumor populations expanded *ex vivo.* Bioluminescence imaging was conducted using the IVIS Spectrum *In Vivo* Imaging System (Perkin Elmer) in accordance with manufacturer protocols. Mice anesthetized with isoflurane were imaged before and after D-Luciferin (dissolved in PBS) injection intra peritoneally (150mg/kg body weight) at equal exposure times to determine bioluminescence signal. A kinetic study of bioluminescent signal after Luciferin injection was performed to determine peak signal time.

### Bioinformatic Analyses {#S25}

For Kaplan Meier analysis, KM Plotter was used([@R28]; [@R42]). The optimal probes to be used for each UPR^mt^ marker were identified using JetSet([@R48]) and were as follows: *SIRT3* (221913_at), *FOXO3a* (217399_s\_at), *SOD2* (215223_s\_at), *SOD1* (200642_at), *NRF1* (204651_at), *LC3B* (208786_s\_at), and *HSP60* (200807_s\_at). Publicly available expression data for primary breast cancers (GEO: GSE11121, GSE12093, GSE12276, GSE1456, GSE16391, GSE2034, GSE2990, GSE3494, GSE5327, GSE6532, GSE7390, and GSE9195) was downloaded and compiled. Normalized expression of UPR^mt^ markers (*SIRT3, FOXO3a, SOD2, SOD1, NRF1, LC3, HSP60*) were averaged for each patient to calculate a UPR^mt^ Expression Score. Patients were ranked from lowest to highest UPR^mt^ Expression Score and the highest third of patients (33.3%, n = 603) were designated UPR^mt-HIGH^ and the bottom two thirds of patients (66.6%, n = 1206) were designated UPR^mt-LOW^. The designations were used as classifiers for Comparative Marker Selection available through GenePattern([@R70]). All genes with a false discovery rate (FDR) less than 0.05 were ranked by Log~2~ Fold Change and this was used for pre-ranked gene set enrichment analysis (GSEA) available through GenePattern ([@R56]; [@R70]; [@R79]). Enrichment scores were determined as a running sum statistic at maximum deviation from zero.

QUANTIFICATION AND STATISTICAL ANLYSIS {#S26}
--------------------------------------

Statistical tests used are described in figure legends with additional detail. Statistical significance was defined as a p value below 0.05. ns = not significant, \* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.001, \*\*\*\* p \< 0.0001. Data displayed as mean ± standard error of the mean (SEM) or mean ± standard deviation (SD) and noted in figure legends. Statistical analyses were performed using GraphPad Prism Software or R.
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![ROS Identifies Invasive Tumor Cells Primed to Upregulate the UPR^mt^ by Mitohormesis\
(A) Female *MMTV-rtTA/TetO-NeuNT* mice given doxycycline water at 0.75 g/L for 7 weeks or 1.5 g/L for 12 weeks.\
(B) Flow cytometry of mitochondrial ROS levels (MitoSOX) in cohort 1 primary tumor (n = 4 mice).\
(C) Flow cytometry of cohort 2 as in (B) (n = 4). ROS− and ROS+ populations isolated by FACS and sub-cultured.\
(D) Representative transwell invasion (scale, 100 μm) n = 3 with ≥ 2 technical replicates.\
(E) ROS− or ROS + cells tail vein injected and metastasis assessed by bioluminescence. Mann-Whitney, two-tailed, \*p \< 0.05, \*\*p \< 0.01, ns = not significant; mean ± SEM; n = 5 mice/group.\
(F) Area under curve of each mouse. Mann-Whitney, two-tailed, \*\*p \< 0.01; mean ± SEM; n = 5 mice/group.\
(G) Western for UPR^mt^ in isolated ROS− and ROS+ subpopulations from (C) before *ex vivo* expansion.\
(H) Flow cytometry of mitochondrial ROS levels on ROS− and + cells cultured *ex vivo*. FACS isolation of ROS− populations of original ROS− and + cells.\
(I) Western for UPR^mt^ in ROS- from (H) after brief *ex vivo* expansion.\
(J) Percent viability of attached cells after 24 h 50 μM menadione. Multiple t tests, Holm-Sidak method, \*p \< 0.05; Mean ± SEM; n = 3 biological replicates with 3 technical replicates.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1530022-f0002){#F1}

![Focal Activation of UPR^mt^ in Primary Murine Tumors and Enrichment of UPR^mt^ in Metastases\
Female *MMTV-rtTA/TetO-NeuNT* mice given doxycycline in water at 1.5 g/L for 12 weeks.\
(A) Primary tumors stained by IHC with UPR^mt^ markers. n = 7 mice; scale, 100 μm.\
(B) Primary tumors and lung metastases from serial sections stained by IHC with UPR^mt^ markers. 1+, 2+ or 3+ scoring system (scale, 10 μm). Samples scored by intensity or intensity × extent. Intensity distribution with representative images (scale, 50 μm). Intensity × extent compared in primary and metastatic lesions. n = 7 mice; 8 primary tumors with 8 regions scored; all lung metastases (14-23/stain) scored. Unpaired t test, two-sided, \*p \< 0.05, \*\*p \< 0.01, \*\*\*\*p \< 0.0001; mean (red line) ± SEM.\
(C) 5 μm serial sections of primary tumors stained with UPR^mt^ markers, pseudocolored, and overlaid (scale, 100 μm). ROI highlighted and enlarged below. SIRT3 (green); FOXO3a (pink); LC3B (purple); NRF1 (red); SOD2 (yellow); HSP60 (blue); SOD1 (orange). n = 7 mice.\
(D) 5 μm serial sections of lung metastases as in (C). n = 7 mice.\
See also [Figure S1](#SD1){ref-type="supplementary-material"} and [Table S6](#SD1){ref-type="supplementary-material"}.](nihms-1530022-f0003){#F2}

![Identification of Invasive, UPR^mt-HIGH^ Subpopulation of Human Cell Lines by Endogenous Mitohormesis\
(A) Invasive subpopulation of MCF7 cells isolated by transwell invasion and sub-cultured to generate MCF7 iteration 1 (I1).\
(B) Representative transwell invasion (scale, 100 μm).\
(C) Flow cytometry of endogenous mitochondrial ROS levels in MCF7 parental (P) and I1.\
(D) Western for UPR^mt^ in MCF7 P and I1.\
(E) ROS+ population of MCF7 isolated by FACS and sub-cultured to generate MCF7 ROS+ cells.\
(F) Representative images of transwell invasion assays (scale, 100 μm).\
(G) Western for UPR^mt^ in MCF7 P and ROS+.\
(H) Invasive subpopulation of MDA-MB-231 P cells isolated by transwell invasion and sub-cultured to generate I1 and repeated to generate I2.\
(I) Representative transwell invasion (scale, 100 μm).\
(J) Flow cytometry of endogenous mitochondrial ROS levels in MDA-MB-231 P, I1, and I2.\
(K) Western for UPR^mt^ markers in MDA-MB-231 P, I1, and I2.\
(L) ROS+ population of MDA-MB-231 cells isolated by FACS and sub-cultured to generate MDA-MB-231 ROS+ cells.\
(M) Representative images of transwell invasion (scale, 100 μm).\
(N) Western for UPR^mt^ in MDA-MB-231 P and ROS+.\
(O) MDA-MB-231 treated with non-targeting siNC1 or siSIRT3. Representative western of UPR^mt^.\
(P) Quantification of UPR^mt^ after siRNA. n = 3 experiments. Unpaired t test, two-sided, \*p \< 0.05, \*\*p \< 0.01, ns = not significant; mean ± SEM.\
(Q) Representative transwell invasion of MDA-MB-231 siNC1 or siSIRT3 (scale, 100 μm). n = 3 experiments with R 3 technical replicates.\
(R) Western for indicated markers in MDA-MB-231 generated with stable shRNA control (shScrambled) or targeting (shSIRT3-345 and shSIRT3-752) constructs in *pLV-H1-CMV-green* vector. Tail vein injection and collected after 4 weeks.\
(S) Metastases visualized in freshly excised lungs using multiphoton microscopy. GFP, green. Collagen, purple (scale, 100 μm). shScrambled n = 5; shSIRT3-345 n = 4; shSIRT3-752 n = 5 mice.\
(T) Whole lung sections from S stained by IF for GFP. Lesions per section counted and size noted as single cells, clusters, or micro-metastases. Total lung lesions compared. Mann-Whitney, two-tailed, \*p \< 0.05, \*\*p \< 0.01; mean ± SEM.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1530022-f0004){#F3}

![Increased Activation of UPR^mt^ in Patients Correlates with Worse Clinical Outcomes and Is Associated with a Distinct Transcriptional Signature\
(A) Heatmap of UPR^mt^ expression in 1809 breast cancer patients. Top ranked tertile (n = 603) called UPR^mt-HIGH^. Estrogen receptor (ER) status displayed. Negative, white; positive, black. Significant correlation: ER negative and UPR^mt-HIGH^. Pearson's chi-square, Yates' continuity correction, p = 2.45e-20, n = 1231.\
(B) Kaplan-Meier (KM) analysis of overall survival (OS) with UPR^mt^ classifier (n = 1402). HR = hazard ratio.\
(C) KM of relapse-free survival (RFS) with UPR^mt^ classifier (n = 3951).\
(D) KM of distant metastasis-free survival (DMFS) with UPR^mt^ classifier (n = 1764).\
(E) KM of RFS in lymph node positive patients with UPR^mt^ classifier (n = 1133).\
(F) Volcano plot UPR^mt-HIGH^ versus UPR^mt-LOW^ patients (n = 1809). Log2 fold change versus false discovery rate (FDR). Significant genes, red (FDR \< 0.05 & log2 fold change R ≥ ± 0.6)\
(G) Gene set enrichment analysis (GSEA) of UPR^mt-HIGH^ versus UPR^mt-LOW^ (n = 1809). Negatively (left) and positively (right) enriched gene ontology terms. Bar length, normalized enrichment score (NES). Bar color, FDR. Gene set source, color code.\
See also [Figure S3](#SD1){ref-type="supplementary-material"} and [Tables S1](#SD2){ref-type="supplementary-material"}, [S2](#SD3){ref-type="supplementary-material"}, [S3](#SD4){ref-type="supplementary-material"}, [S4](#SD5){ref-type="supplementary-material"}, and [S5](#SD6){ref-type="supplementary-material"}.](nihms-1530022-f0005){#F4}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                        SOURCE                                                        IDENTIFIER
  -------------------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                               
  Rabbit monoclonal anti-SIRT3 (C73E3)                                       Cell Signaling Technology                                     Cat\#2627; RRID:AB_2188622
  Rabbit polyclonal anti-SIRT3                                               Millipore                                                     Cat\#07-1596; RRID:AB_1977497
  Mouse monoclonal anti-HSP60                                                BD Biosciences                                                Cat\#611563; RRID:AB_399009
  Rabbit monoclonal anti-ATF5 \[EPR18286\]                                   Abcam                                                         Cat\#ab184923; RRID:AB_2800462
  Mouse monoclonal anti-NRF1                                                 Abcam                                                         Cat\#ab55744; RRID:AB_2154534
  Rabbit monoclonal anti-CLPP \[EPR7133\]                                    Abcam                                                         Cat\#ab124822; RRID:AB_10975619
  Rabbit polyclonal anti-SOD-1 (FL-154)                                      Santa Cruz Biotechnology                                      Cat\#sc-11407; RRID:AB_2193779
  Rabbit monoclonal anti-FOXO3a (75D8)                                       Cell Signaling Technology                                     Cat\#2497; RRID:AB_836876
  Mouse monoclonal anti-Actin, clone C4                                      Millipore                                                     Cat\#MAB1501; RRID:AB_2223041
  Rabbit polyclonal anti-Mn-SOD                                              Millipore                                                     Cat\#06-984; RRID:AB_310325
  Rabbit polyclonal anti-LC3                                                 MBL International                                             Cat\#PM036; RRID:AB_2274121
  Mouse monoclonal anti-SDHA \[2E3GC12FB2AE2\]                               Abcam                                                         Cat\#ab14715; RRID:AB_301433
  Rabbit polyclonal anti-MTCO1                                               Abcam                                                         Cat\#ab45918; RRID:AB_944283
  Mouse monoclonal anti-GFP (B-2)                                            Santa Cruz Biotechnology                                      Cat\#sc-9996; RRID:AB_627695
  Rabbit monoclonal anti-NRF2 (D1Z9C)                                        Cell Signaling Technology                                     Cat\#12721; RRID:AB_2715528
  Mouse monoclonal anti-ErbB2 (3B5)                                          Abcam                                                         Cat\#ab16901; RRID:AB_443537
  Rabbit polyclonal anti-SIRT3                                               Abcam                                                         Cat\#ab86671; RRID:AB_10861832
  Rabbit monoclonal anti-FOXO3a (D19A7)                                      Cell Signaling Technology                                     Cat\#12829; RRID:AB_2636990
  HRP Goat anti-Mouse IgG                                                    Jackson ImmunoResearch Labs                                   Cat\#115-035-003; RRID:AB_10015289
  HRP Goat anti-Rabbit IgG                                                   Thermo Fisher Scientific                                      Cat\#65-6120; RRID:AB_2533967
  HRP Digital anti-Mouse IgG                                                 Kindle Biosciences                                            Cat\#R1005; RRID:AB_2800463
  HRP Digital anti-Rabbit IgG                                                Kindle Biosciences                                            Cat\#R1006; RRID:AB_2800464
  Biotin Goat anti-Mouse IgG                                                 Jackson ImmunoResearch Labs                                   Cat\#115-065-205; RRID:AB_2338571
  Biotin Donkey anti-Rabbit IgG                                              Jackson ImmunoResearch Labs                                   Cat\#711-065-152; RRID:AB_2340593
  Alexa Flour 488 Goat anti-Mouse IgG                                        Thermo Fisher Scientific                                      Cat\#A-11001; RRID:AB_2534069
  Bacterial and Virus Strains                                                                                                              
  NEB Stable Competent *E. coli* (High Efficiency)                           New England BioLabs                                           Cat\#3040
  Chemicals, Peptides, and Recombinant Proteins                                                                                            
  Antibody Diluent, Normal                                                   MP Biomedicals                                                Cat\#08980641; RRID:AB_2335238
  Streptavidin, Horseradish Peroxidase concentrate for IHC                   Vector Laboratories                                           Cat\#SA-5004; RRID:AB_2336509
  Lipofectamine 2000 Transfection Reagent                                    Thermo Fisher Scientific                                      Cat\#11668019
  Lipofectamine RNAiMAX Transfection Reagent                                 Thermo Fisher Scientific                                      Cat\#13778100
  Collagen I, Rat Tail                                                       Corning                                                       Cat\#354236
  Polybrene                                                                  Santa Cruz Biotechnology                                      Cat\#sc-134220
  Matrigel Growth Factor Reducted (GFR) Basement Membrane Matrix             Corning                                                       Cat\#354230
  MitoSOX Red Mitochondrail Superoxide Indicator                             Thermo Fisher Scientific                                      Cat\#M36008
  gamitrinib-triphenylphosphonium (G-TPP)                                    [@R34]                                                        N/A
  Doxycycline hyclate                                                        Sigma-Aldrich                                                 Cat\#D9891
  Amoxicillin trihydrate                                                     Sigma-Aldrich                                                 Cat\#PHR1127
  D-Luciferin                                                                Sigma-Aldrich                                                 Cat\#L9504
  Collagenase                                                                Sigma-Aldrich                                                 Cat\#C9891
  Red Blood Cell Lysing Buffer Hybri-Max                                     Sigma-Aldrich                                                 Cat\#R7757
  Critical Commercial Assays                                                                                                               
  AEC Peroxidase Substrate Kit                                               Vector Laboratories                                           Cat\#SK-4200; RRID:AB_2336076
  Plasmid Maxi Kit                                                           QIAGEN                                                        Cat\#12165
  Cell Culture Insert, Transparent PET Membrane, 8 μm pore size              Corning                                                       Cat\#353097; Cat\#353093
  Hema 3 Manual Staining System and Stat Pack                                Fisher Scientific                                             Cat\#23-123869
  Deposited Data                                                                                                                           
  Primary breast cancer gene expression data                                 Gene Expression Omnibus                                       GEO: GSE11121, GSE12093, GSE12276, GSE1456, GSE16391, GSE2034, GSE2990, GSE3494, GSE5327, GSE6532, GSE7390, and GSE9195
  TCGA Breast Cancer Dataset                                                 National Cancer Institute GDC Data Portal                     TGCA-BRCA, DbGAP Study Accession \#phs000178
  Experimental Models: Cell Lines                                                                                                          
  MCF7                                                                       ATCC                                                          Cat\#HTB-22
  MDA-MB-231                                                                 ATCC                                                          Cat\#HTB-26
  Lenti-X 293T                                                               Takara Clontech                                               Cat\#632180
  MMTV-rtTA/TetO-NeuNT mammary tumor cell lines                              This Paper                                                    N/A
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  Software and Algorithms                                                                                                                  
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###### Highlights

-   Evidence of endogenous mitohormesis in breast cancer cell lines and primary tumors

-   Mitohormetic priming of tumor cells leads to increased basal activation of the UPR^mt^

-   Mitohormesis and UPR^mt^ activation makes cancer cells more invasive and metastatic

-   UPR^mt^ enriched breast cancer patients have worse clinical outcomes
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